Symbicort Approval History

• FDA approved: Yes (First approved July 21st, 2006)
• Brand name: Symbicort
• Generic name: budesonide and formoterol
• Dosage form: Inhaler
• Company: AstraZeneca
• Treatment for: Asthma, Maintenance, COPD, Maintenance

Symbicort (budesonide and formoterol) is a combination of a corticosteroid and a long-acting bronchodilator indicated for the long-term maintenance treatment of asthma and the maintenance treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and emphysema.

Development History and FDA Approval Process for Symbicort

Date	Article
Jan 26, 2017	Symbicort Approved for the Treatment of Asthma in Patients 6 to 12 Years of Age
Feb 27, 2009	FDA Approves Symbicort for Chronic Obstructive Pulmonary Disease (COPD)
Jul 22, 2006	AstraZeneca’s Symbicort (budesonide/formoterol) Treatment For Asthma Approved By The FDA
Sep 23, 2005	AstraZeneca Submits New Drug Application (NDA) to FDA for Symbicort Maintenance Treatment of Asthma

Disclaimer: Every effort has been made to ensure that the information provided here is accurate, up-to-date and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. This information has been compiled for use by healthcare practitioners and consumers in the United States. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective or appropriate for any given patient. If you have questions about the substances you are taking, check with your doctor, nurse or pharmacist.